Aegis Sciences Corporation

Aegis Sciences Corporation

David Schwab founded Aegis Sciences Corporation in 1990 as a forensic toxicology laboratory in Nashville, Tennessee. The firm serves clinicians, public health agencies, and athletic programs — providing definitive drug testing that goes beyond standard immunoassay screens to identify specific prescription and designer compounds. This remit places Aegis at the intersection of the opioid crisis response and anti-doping enforcement. Aegis deploys instrumentation and methodology across three core verticals: healthcare testing, sports anti-doping, and biopharma molecular diagnostics. Its healthcare products — including Aegis PainComp for chronic pain monitoring and AcuRise ID for mental health and substance use disorder — test for medication adherence and illicit or non-prescribed substances. The sports testing division, operating out of the Wilma Rudolph Sports Testing Laboratory, screens for performance-enhancing drugs like anabolic steroids, stimulants, and diuretics for clients such as the NCAA and professional leagues. A third segment supports clinical trials and pharmacogenetic testing. Confirmed operational regions cover the United States, with state-level licensure spanning California, New York, Maryland, Pennsylvania, and others. Aegis holds accreditations from the College of American Pathologists and maintains DEA licensing. The firm launched an internal dashboard to track novel psychoactive substances across its national specimen pool, aiming to give public health officials real-time visibility into synthetic drug trends. This analytical infrastructure supports a client base that includes clinicians treating Medicare, Managed Medicaid, and commercially insured populations, as well as workers' compensation programs. Aegis distinguishes itself through specimen-level forensic certainty grafted onto a traditional reference-lab business model. Rather than competing with high-volume clinical labs, it competes on molecular specificity — resolving compounds that standard panels miss, such as designer benzodiazepines and synthetic opioids — a differentiation that aligns with heightened DEA and FDA scrutiny on prescription monitoring.